A chronological record of peer-reviewed Tirzepatide research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Tirzepatideworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Dual GIP/GLP-1 Agonism. Primary indications investigated: Weight management, Type 2 diabetes.
Head-to-head trial showing tirzepatide 15mg produced 20.2% weight loss versus 13.7% for semaglutide 2.4mg over 72 weeks.
Phase 3 trial in adults with obesity and type 2 diabetes showing tirzepatide 15mg produced 14.7% weight loss and 2.1 percentage point HbA1c reduction.
Trial showing tirzepatide produced additional 18.4% weight loss on top of 6% from intensive lifestyle intervention, vs 2.5% weight regain with placebo.
Cardiovascular safety trial of tirzepatide in type 2 diabetes with established cardiovascular disease.
Pilot trial demonstrating tirzepatide-induced weight loss significantly improved obstructive sleep apnea severity.
Trial demonstrating tirzepatide slowed diabetic kidney disease progression with reduced albuminuria and eGFR decline.
Phase 2b liver biopsy trial showing tirzepatide reduced NASH activity and fibrosis compared to placebo.
Trial demonstrating tirzepatide improved triglycerides and LDL cholesterol independent of weight loss.
Pivotal Phase 3 RCT showing tirzepatide 15mg produced 22.5% mean weight loss over 72 weeks in adults with obesity, the highest for any approved medication.
Phase 3b maintenance trial showing sustained weight loss with continued tirzepatide and rapid weight regain after discontinuation.
Phase 3 trial evaluating tirzepatide efficacy and safety in East Asian patients with type 2 diabetes.
Systematic review and meta-analysis of tirzepatide trials across all phases demonstrating consistent weight loss superiority.
Exploratory analysis showing tirzepatide-induced weight loss produced significant blood pressure reductions.
Head-to-head trial showing all tirzepatide doses were superior to semaglutide 1.0mg for HbA1c reduction in type 2 diabetes.
Phase 3 trial of tirzepatide 15mg weekly showing superior weight loss versus semaglutide in patients with obesity.
Phase 3 trial demonstrating tirzepatide 10mg weekly superior HbA1c reduction and weight loss compared to insulin degludec.
Phase 3 head-to-head trial demonstrating tirzepatide superior to semaglutide for glycemic control in type 2 diabetes.
Phase 3 trial of tirzepatide in patients already treated with metformin monotherapy.
Phase 3 trial of tirzepatide as add-on to insulin therapy in type 2 diabetes patients.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Tirzepatide is L5 (FDA Approved): fda-approved for at least one human indication. Treat each study as one data point, not a conclusion.
PeptideMark indexes 180 studies on Tirzepatide: 95 human studies, 40 animal studies, 15 in-vitro, and 30 reviews. The current evidence level is L5 — fda approved.
The earliest indexed peer-reviewed study on Tirzepatide in the PeptideMark library was published in 2021 (New England Journal of Medicine). Research activity has continued through 2024.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Yes. Recent publications on Tirzepatide appear as recently as 2024, indicating ongoing investigation. See the research log on this page for the specific study.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.